PPT-Impact of INSTI and TAF-related BMI changes and risk on hypertension and dyslipidemia

Dathan M Byonanebye Mark N Polizzotto Fernando Maltez Andri Rauch Katharina GrabmeierPfistershammer Ferdinand Wit Stéphane De Wit Antonella Castagna Antonella DArminio Monforte Cristina Mussini JanChristian Wasmuth Eric . Shannon Harris, DNP, FNP. Objectives. Causes of hypertension. Classifications of hypertension. Risk factors. Diagnosis . Complications. Management . Final thoughts. Hypertension. The #1 modifiable risk factor for stroke. Estudio GS-US-311-1089 . Estudio GS-US-366-1216 . Estudio GS-US-366-1160 . . Diseño. Endpoints. Primario: proporción de pacientes . con C. V . < 50 c/mL a S48 (ITT, . snapshot. ) ; no inferioridad si el margen inferior de IC95% de dos colas para la diferencia = - 8%, poder 85%. 2013 ACC/AHA Guideline on the. Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. IMPROVE-IT. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia. Circulation 2014;129:587-597. Teaching Tool: Hyperfiltration Early Sign of Hypertension and Diabetes. J Am Soc Nephrol 2017;28:1023-1039. Hyperfiltration Early in . Diabetic Nephropathy. Circulation 2016;134:752-772. QDMRK. SPRING-2. ONCEMRK. GS-US-380-1489. GS-US-380-1490. GS-US-380-1490. Design. Objective. Non inferiority of BIC/F/TAF at W48: % HIV RNA < 50 c/mL by intention . to treat, snapshot analysis (lower margin of the 2-sided 95.002% CI for . in a Single-Tablet Regimen . in Initial HIV-1 Therapy. Combined Primary Results of . Studies GS-US-292-0104 and GS-US-292-0111. David Wohl. 1. , Anton Pozniak. 2. , Melanie Thompson. 3. , Edwin DeJesus. /Lipid management in . Diabetes. Dr.Zahra. . davoudi. Endocrinology department of . Loghman. Hakim Hospital, . Shahid. . Beheshti. University of Medical Sciences. A . 65 year-old woman . with medical history of . Clinics (www.dhs.state.mn.us) ProcedureRisk AssessmentThe following are examples of recommended risk factors that can be identified through the personal and family health history and physical measurem Samir Mustafa Smisim Medical Director Of training Dept SRCA, Saudi Arabia Abstract: Introduction: Gestational Hypertension can lead to a serious con - Preeclampsia,referredtoToxemia.Hyperten - sion d Study GS-366-1216. Switch from TDF to TAF, each with RPV and FTC. Study GS-366-1216: Design. Source: . Orkin. C et al. Lancet HIV. 2017;4:e195-e204.. *. NOTE. :. of 632 participants randomized, 2 were never treated (630 individuals treated). and . Virologic. Outcomes . for Treatment-experienced . People Living with HIV Switching to MTR or STR ART since 2018 . Ben Chastek. 1. , Amy Anderson. 1. , Joshua Gruber. 2. , Sunil Majethia. 2. , Woodie Zachry. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. Study 112. Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment. Study 112: . Design. Source: . Pozniak. A, et al. J . Acquir. Immune . Defic. . Syndr. . 2016;71:530-7.. Baseline ART*. (n = 242). Study Design: Study 112. a . tool for assessing applicability and scalability of WASH Technologies for providing sustainable . service delivery. Benedict Tuffuor – . TREND. Regional LA, Ho – 24. th. July, 2013. Uptake [number of units providing services].